Pharmacists have been identified by the CDC as key professionals in achieving one of the CDC’s goals of Ending the HIV Epidemic in the U.S. by preventing HIV infection. Below are some of the most common questions received at the AETC National Clinician Consultation Center (NCCC) from pharmacists abo...
We recognize the work of our AETC colleagues who dedicate additional time and resources to research beyond the scope of the AETC Program. The following is a compilation of HIV-related peer-reviewed studies produced by AETC-affiliated researchers and faculty, published in 2021.
If you're aware of othe...
Imagine living in a state with the second highest rate of chlamydia and the third highest rate of congenital syphilis infections in the United States (U.S.) in 2018. Our first thought was how can this be, and our second thought was what can we do to overcome this? When we looked at the 2019 U.S. Cen...
The FDA recently approved the use of an extended-release injectable formulation of the integrase inhibitor cabotegravir (CAB) for preexposure prophylaxis (PrEP) for adults and adolescents at risk for HIV infection. After two initial intramuscular (IM) injections given 1 month apart, it is administer...
In December 2021, the U.S. Centers for Disease Control and Prevention issued thoroughly revised and updated PrEP guidelines. The guidelines include important new information on the use of oral PrEP (TDF/FTC and TAF/FTC) and recommendations on the use of injectable cabotegravir (CAB) as PrEP.
Key upda...
Chlamydia trachomatis (CT) and Neisseria gonorrhoeae (GC) are the two most common bacterial sexually transmitted infections in the United States. The incidence of CT and GC have increased consistently since 2014, and current rates are at an all-time high. CT and GC infections are treatable with anti...
The FLAIR study evaluated the efficacy and safety of the long-acting injectable regimen of cabotegravir (CAB) + rilpivirine (RPV) in previously ART-naïve individuals who switched to CAB+RPV after viral suppression on a standard 3-drug oral regimen (dolutegravir [DTG]/ABC/3TC). At both 48 weeks (the...
Lenacapavir (LEN) is a novel investigational long-acting injectable ARV that is administered every 6 months by subcutaneous (SC) injection. It is an HIV-1 capsid inhibitor that acts at several points in the HIV life cycle. As a novel class, has full activity against viruses with resistance to the NR...
TANGO is a randomized open-label study in which subjects with virologic suppression on standard 3-drug TAF-based ART either switched to the 2-drug regimen of dolutegravir (DTG)/lamivudine (3TC) n = 369) or continued their baseline ART (n = 372). Previously published data showed no significant differ...
While sexually transmitted infections (STIs) affect individuals of all ages, STIs take a hefty toll on young adults with HIV in Washington, DC. Despite continual public health efforts to reduce the rate of new STI infections, adolescents and young adults persist as the majority of new STI diagnoses...
With the current increase in COVID-19 cases in the United States (U.S.), this information will benefit not just dentists but all healthcare providers.
As of December 20, 2020, the following states are permitting dentists to administer the COVID-19 vaccine: Arkansas, Idaho, Louisiana, Oklahoma, Oregon...
Even before the COVID-19 pandemic, many adults faced barriers to receiving oral health care, increasing their risk of infection and the need for emergency hospital visits. And now, as unmet dental needs worsen while the pandemic lingers and people suffer the loss of jobs and dental insurance, provid...
Study shows SARS-CoV-2 infection risk at the dentist’s office is low.
A new study’s findings dispel the misconception that patients and providers are at high risk of catching COVID-19 at the dentist’s office.
SARS-CoV-2 spreads mainly through respiratory droplets, and dental procedures are known to pr...
National Alliance of State & Territorial AIDS Directors' (NASTAD) Center for Innovation and Engagement (CIE)
As public health professionals, educators, and HIV care providers, it is imperative that we develop truly innovative approaches to address the health and social needs of communities and a...
The AETC Program's new resource combines the most up-to-date, HIV screening, prevention, and care resources in one mobile app, to provide access to essential point-of-care information and expert clinical support with just one touch.
HIV Care Tools is for busy clinicians from novice-to-expert, clinic...
Working on the front lines of COVID-19, infectious diseases specialist and South Central AIDS Education and Training Center (SCAETC) Medical Director at Access Health Louisiana, Dr. MarkAlain Dery, observed that other healthcare professionals were getting lost in both the bulk and complexity of the...
CHICAGO (Feb. 12, 2021) – The American Dental Association (ADA) has been tracking developments of tongue and mouth issues COVID-19 patients experience since early on in the pandemic. Oral health is an important and vital part of overall health, and the ADA is continuing to examine the connection bet...
Even before COVID-19 inexorably changed social and clinical protocols, dental offices dealt with patients who claimed to “know better” than their providers when it came to health risks. From unvaccinated patients to incomplete health histories, failure to cooperate results in ethical and legal chall...
The relationship between oral health and overall health has been well established for many comorbidities including diabetes and cardiovascular disease.
We are still learning about COVID-19 and how it affects people living with HIV. Based on limited data, people with HIV who are on effective HIV treat...
We close out 2020 by recognizing the productivity of the AETC community despite this year’s challenges and setbacks. In addition to restructuring and reimagining their clinical settings and AETC-related programming due to the COVID-19 pandemic, AETC members were also researching and reexamining HIV...
